Silence Therapeutics
SLN
34 hedge funds and large institutions have $345M invested in Silence Therapeutics in 2023 Q4 according to their latest regulatory filings, with 8 funds opening new positions, 9 increasing their positions, 6 reducing their positions, and 2 closing their positions.
300% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 2
84% more capital invested
Capital invested by funds: $188M → $345M (+$157M)
50% more funds holding in top 10
Funds holding in top 10: 4 → 6 (+2)
50% more repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 6
21% more funds holding
Funds holding: 28 → 34 (+6)
0.82% more ownership
Funds ownership: 18.29% → 19.11% (+0.82%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VC
Vivo Capital
Palo Alto,
California
|
+$5.73M |
| 2 |
AG
Artal Group
Luxembourg
|
+$5.61M |
| 3 |
LGM
Logos Global Management
San Francisco,
California
|
+$4.49M |
| 4 |
LOAME
Lombard Odier Asset Management (Europe)
London,
United Kingdom
|
+$1.9M |
| 5 |
Morgan Stanley
New York
|
+$812K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACM
Aquilo Capital Management
San Francisco,
California
|
-$3.02M |
| 2 |
Goldman Sachs
New York
|
-$2.62M |
| 3 |
LOAMU
Lombard Odier Asset Management (USA)
New York
|
-$2.01M |
| 4 |
WP
Woodline Partners
San Francisco,
California
|
-$1.32M |
| 5 |
CF
Cantor Fitzgerald
New York
|
-$240K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
SG Americas Securities
New York
| $110K | +$71.1K | +6,333 | New |
|
27
Lazard Asset Management
New York
| $38K | +$1.12K | +100 | +5% |
|
|
GI
28
GAMMA Investing
Foster City,
California
| $20.7K | +$10.3K | +918 | New |
|
29
Bank of America
Charlotte,
North Carolina
| $18.7K | +$5.91K | +526 | +96% |
|
|
TRCT
30
Tower Research Capital (TRC)
New York
| $12.3K | +$7.94K | +707 | New |
|
|
ACM
31
ADAR1 Capital Management
Austin,
Texas
| $3.3K | +$2.13K | +190 | New |
|
32
Qube Research & Technologies (QRT)
London,
United Kingdom
| $3.09K | – | – | – |
|
|
SPIA
33
Steward Partners Investment Advisory
New York
| $1.74K | – | – | – |
|
34
RhumbLine Advisers
Boston,
Massachusetts
| $86 | – | – | – |
|
|
35
Goldman Sachs
New York
| – | -$2.62M | -266,667 | Closed |
|
36
Deutsche Bank
Frankfurt Am Main Ge,
Germany
| – | -$6.09K | -620 | Closed |
|
SLN Hedge Fund Activity: Q4 2023 in Review
34 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Silence Therapeutics (SLN) for Q4 2023, worth a combined $345M — up 84% from $188M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new SLN positions and 2 closed out — a net gain of 6 holders — while 9 added to existing stakes and 6 trimmed.
The largest buyer was Vivo Capital, opening a new position worth an estimated $5.73M. The largest seller was Aquilo Capital Management, cutting an estimated $3.02M.
- 34 institutional investors held Silence Therapeutics (SLN) as of Q4 2023, up from 28 in Q3 2023.
- Funds reported $345M of Silence Therapeutics stock for Q4 2023, up 84% quarter-over-quarter.
- 8 funds opened new Silence Therapeutics positions in Q4 2023 and 2 closed out, a net change of +6 holders.
- The largest Silence Therapeutics buyer in Q4 2023 was Vivo Capital, an estimated $5.73M added.
- The largest Silence Therapeutics seller in Q4 2023 was Aquilo Capital Management, an estimated $3.02M sold.
Based on aggregated 13F filings for Q4 2023.